Versigent PLC

8-K10-QForm 413G

Market Movers (8-K)

NYSE
Versigent PLC announced robust second quarter 2026 financial results, featuring 10.8% net sales growth, a significant increase in Adjusted EBITDA, and the initiation of a quarterly dividend, while also raising full-year net sales guidance.
Better than expected

Quarterly Earnings (10-Q)

NYSE
Versigent PLC announced a 10% increase in net sales for the first six months of 2026, driven by volume growth and improved operational performance, alongside a significant increase in cash and cash equivalents.
Capital raise

Insider Trading (Form 4)

See all →
NYSE
Amy E Alving, a Director of Versigent PLC, received 15 shares of common stock on September 18, 2026.
NYSE
Kevin P Clark, a Director of Versigent PLC, received 15 shares of common stock on September 18, 2026.
NYSE
Sharon Vinci, Chief People Officer of Versigent PLC, received 173 shares of common stock on September 18, 2026.
NYSE
Jason Celian, Chief Accounting Officer of Versigent PLC, received 26 shares of common stock on September 18, 2026.
NYSE
Douglas R Ostermann, Chief Financial Officer of Versigent PLC, received 481 shares of common stock on September 18, 2026.
NYSE
Joseph T. Liotine, CEO and Director and a Director of Versigent PLC, received 489 shares of common stock on September 18, 2026.

Schedule 13G - Passive Investments

NYSE
Vanguard Portfolio Management has reported beneficial ownership of 6.01% of Versigent PLC's common stock as of June 30, 2026.
NYSE
Vanguard Capital Management has reported beneficial ownership of 3,870,983 shares, representing 5.46% of Versigent PLC's common stock, as of June 30, 2026.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 15.0% of Versigent PLC's common stock as of June 30, 2026.